These results support the hypothesis that EPA/DHA protects against PAH-mediated lung tumorigenesis by decreasing the expression of DNMT and EZH2, which in turn leads to the reversal of RUNX3 silencing and, therefore, results in the increased expression of RUNX3. The gene discussed is RUNX3; the disease is pulmonary arterial hypertension.